Recalls You Should Know About—Week of February 18, 2018

In case you missed them, we've compiled recalls that you should know about from this past week.

The following are recalls that you should know about from this past week:

Triple T Specialty Meats Inc. Recalls Chicken Salad Products Due to Possible Salmonella Contamination—February 21, 2018

The US Department of Agriculture’s Food Safety and Inspection Service announced that Triple T. Specialty Meats, Inc. is recalling about 20,630 pounds of ready-to-eat chicken salad products that may potentially be contaminated with Salmonella Typhimurium.

The products were produced on dates ranging from January 2, 2018, and February 7, 2018. According to the USDA, the recalled products bear establishment number “P-21011” inside the USDA mark of inspection. The items were shipped to Fareway grocery stores in 5 states: Iowa, Illinois, Minnesota, Nebraska, and South Dakota.

The CDC has since announced a multistate outbreak regarding cases linked to the contaminated product. For updated case counts, be sure to check out the Contagion® Outbreak Monitor.

Read more about the chicken salad recall.

Hospira Issues A Voluntary Nationwide Recall For Labetalol Hydrochloride Injection, USP, Due To The Potential Of Cracked Glass At The Rim Surface Of The Vials—February 23, 2018

Pfizer’s Hospira, Inc. is voluntarily recalling 3 lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial (NDC 0409-2267-20), and 1 lot of Labetalol Hydrochloride Injection, USP, Novaplus (NDC 0409-2267-25) to the hospital/institution level. The company has decided to recall the product due to the discovery of cracks on the rim surface of the vials for these lots, which is covered by the stopper and crimp seal.

According to the US Food and Drug Administration, cracked vials could result in a lack of sterility assurance for the product, which could result in several adverse events including fever, chills, sepsis, or invasive systemic infections in patients. However, as of publish date, the company has yet to receive reports of adverse events associated with the recalled product.

Read more about the Labetalol Hydrochloride Injection recall.